PTC Therapeutics
PTCT
115 hedge funds and large institutions have $408M invested in PTC Therapeutics in 2016 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 39 increasing their positions, 36 reducing their positions, and 19 closing their positions.
102% more capital invested
Capital invested by funds: $202M → $408M (+$206M)
59% more call options, than puts
Call options by funds: $14.6M | Put options by funds: $9.19M
8% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 36
3% less funds holding
Funds holding: 118 → 115 (-3)
11% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$5.87M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.32M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$4.06M |
| 4 |
Renaissance Technologies
New York
|
+$3.66M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$3.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$10.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.91M |
| 4 |
Jennison Associates
New York
|
-$3.13M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.46M |
PTCT Hedge Fund Activity: Q3 2016 in Review
115 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2016, worth a combined $408M — up 102% from $202M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of PTCT and 17 opened new positions — a net loss of 2 holders — while 36 trimmed existing stakes and 39 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $5.87M. The largest seller was Pictet Asset Management (UK), exiting entirely with an estimated $10.8M sold.
- 115 institutional investors held PTC Therapeutics (PTCT) as of Q3 2016, down from 118 in Q2 2016.
- Funds reported $408M of PTC Therapeutics stock for Q3 2016, up 102% quarter-over-quarter.
- 17 funds opened new PTC Therapeutics positions in Q3 2016 and 19 closed out, a net change of -2 holders.
- The largest PTC Therapeutics buyer in Q3 2016 was D.E. Shaw & Co, an estimated $5.87M added.
- The largest PTC Therapeutics seller in Q3 2016 was Pictet Asset Management (UK), an estimated $10.8M sold.
Based on aggregated 13F filings for Q3 2016.